‘Global Pharma Clinical Trial Services Market Worth $61.92bn In 2021’ Says Visiongain Report

15 August 2018
Pharma

Visiongain’s new report Pharma Clinical Trial Services Market and Industry Forecast 2017-2027: Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-Users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Diseases indicates that the pharma clinical trial sales market will see $61.92bn in spending in 2021.

The pharma clinical trial services market is expected to grow at a CAGR of 9.5% in the first half of the forecast period. The market is expected to grow at a CAGR of 9.8% from 2016-2027. The pharma clinical trial services market is estimated at $39.56bn in 2016 dominated by the late-phase services, which held 56% of share.
The lead analyst of the report said: “The pharma clinical trial services market is driven by several factors, which include the rise in research and development activities by biopharmaceutical organizations, increasing importance of contract research organizations in the emerging markets, and growth in biopharmaceutical research and development expenditures.
However, challenges such as patient recruitment and retention as well as regulatory challenges are some of the factors hampering the growth of this market.”
The 188-page report contains 145 charts that add visual analysis in order to explain the developing trends within the pharma clinical trial services market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments by type of services (early phase, late phase and other services), end-users (pharma, biotech companies and other end-users) and therapeutic area (Cancer, Cardiovascular, CNS, Infectious Diseases, Metabolic Diseases and other Diseases).
The 188-page report offers market forecasts for the US, Rest of North America, Germany, UK, France, Italy, Spain, Russia, Central and Eastern Europe, Rest of Europe, China, Japan, India, South Korea, Rest of APAC, Latin America, Brazil, Middle East and Africa.

Moreover, our work discusses the leading companies in the pharma clinical trial services market.

The report Pharma Clinical Trial Services Market and Industry Forecast 2017-2027: Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-Users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Diseases report will be of value to anyone who wants to better understand the pharma clinical trial services market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharma clinical trial services market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever